Rx Product News (October 2017)

Pharmacy Times, October 2017 Diabetes, Volume 83, Issue 10

Read about the new Rx products featured in October.

Ironwood Pharmaceuticals

INDICATION: The FDA has approved lesinurad and allopurinol (Duzallo) fixed-dose combination treatment for hyperuricemia in patients with uncontrolled gout.

DOSAGE: Tablet: 200 mg lesinurad and 300 mg allopurinol, or 200 mg lesinurad and 200 mg allopurinol

FOR MORE INFORMATION: ironwoodpharma.com

BESPONSAMANUFACTURED BY: Pfizer

INDICATION: The FDA has approved inotuzumab ozogamicin (Besponsa) to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

DOSAGE: Injection: 0.9 mg

FOR MORE INFORMATION: pfizer.com

MAVYRETMANUFACTURED BY: AbbVie

INDICATION: The FDA has approved glecaprevir/pibrentasvir (Mavyret), a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus infection across all major genotypes.

DOSAGE: Tablet: 100 mg glecaprevir and 40 mg pibrentasvir

FOR MORE INFORMATION: abbvie.com

VYXEOSMANUFACTURED BY: Jazz Pharmaceuticals

INDICATION: The FDA has approved daunorubicin and cytarabine (Vyxeos) liposome for injection to treat adults with 2 types of acute myeloid leukemia (AML). Vyxeos is indicated to treat adults with newly diagnosed therapy related-AML or AML myelodyplasia-related change.

DOSAGE: Injection: 44 mg daunorubicin and 100 mg cytarabine

FOR MORE INFORMATION: jazzpharma.com